TRW AUTOMOTIVE HOLDINGS CORP. Common Stock Underwriting Agreement
EXHIBIT 1.1
EXECUTION COPY
Common Stock
May 29, 0000
Xxxx xx Xxxxxxx Securities LLC
0 Xxxx 00xx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
0 Xxxx 00xx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
The persons named in Schedule 2 hereto (each, a “Selling Stockholder” and together,
the “Selling Stockholders”), propose severally, subject to the terms and conditions stated
herein, to sell to you (“you” or the “Underwriter”) an aggregate of 11,000,000
shares (the “Shares”), par value $.01 per share (“Stock”) of TRW Automotive
Holdings Corp., a Delaware corporation (the “Company”). The number of Shares to be sold by
each Selling Stockholder is the number of Shares set forth opposite the name of such Selling
Stockholder in Schedule 2 hereto.
1. (i) The Company represents and warrants to, and agrees with, the Underwriter that:
(a) An “automatic shelf registration statement” as defined under Rule 405 under the
Securities Act of 1933, as amended (the “Act”) on Form S-3 (File No. 333-138457) in
respect of the Shares has been filed with the Securities and Exchange Commission (the
“Commission”) not earlier than three years prior to the date hereof; such
registration statement, and any post-effective amendment thereto, became effective on
filing; and no stop order suspending the effectiveness of such registration statement or any
part thereof has been issued and no proceeding for that purpose has been initiated or, to
the knowledge of the Company, threatened by the Commission, and no notice of objection of
the Commission to the use of such registration statement or any post-effective amendment
thereto pursuant to Rule 401(g)(2) under the Act has been received by the Company (the base
prospectus filed as part of such registration statement, in the form in which it has most
recently been filed with the Commission on or prior to the date of this Agreement, is
hereinafter called the “Basic Prospectus”; any preliminary prospectus (including any
preliminary prospectus supplement) relating to the Shares filed with the Commission pursuant
to Rule 424(b) under the Act is hereinafter called a “Preliminary Prospectus”; the
various parts of such registration statement, including (x) documents incorporated by
reference therein, (y) all exhibits thereto and (z) any prospectus supplement relating to
the Shares that is filed with the Commission and deemed by virtue of Rule 430B to be part of
such registration statement, each as amended at the time such part of the registration
statement became effective, are hereinafter collectively called the “Registration
Statement”; the Basic Prospectus, as amended and supplemented immediately prior to the
Applicable Time (as defined in Section 1(i)(c) hereof), is hereinafter called the
“Pricing
Prospectus”; the form of the final prospectus relating to the Shares filed with
the Commission pursuant to Rule 424(b) under the Act in accordance with Section 4(i)(a)
hereof is hereinafter called the “Prospectus”; any reference herein to the Basic
Prospectus, the Pricing Prospectus, any Preliminary Prospectus or the Prospectus shall be
deemed to refer to and include the documents incorporated by reference therein pursuant to
Item 12 of Form S-3 under the Act, as of the date of such prospectus; any reference to any
amendment or supplement to the Basic Prospectus, any Preliminary Prospectus or the
Prospectus shall be deemed to refer to and include any post-effective amendment to the
Registration Statement, any prospectus supplement relating to the Shares filed with the
Commission pursuant to Rule 424(b) under the Act and any documents filed under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), and incorporated
therein, in each case after the date of the Basic Prospectus, such Preliminary Prospectus,
or the Prospectus, as the case may be; any reference to any amendment to the Registration
Statement shall be deemed to refer to and include any annual report of the Company filed
pursuant to Section 13(a) or 15(d) of the Exchange Act after the effective date of the
Registration Statement that is incorporated by reference in the Registration Statement; and
any “issuer free writing prospectus” as defined in Rule 433 under the Act relating to the
Shares is hereinafter called an “Issuer Free Writing Prospectus”);
(b) No order preventing or suspending the use of any Preliminary Prospectus or any
Issuer Free Writing Prospectus has been issued by the Commission, and each Preliminary
Prospectus, at the time of filing thereof, conformed in all material respects to the
requirements of the Act and the rules and regulations of the Commission thereunder, and did
not contain an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however,
that this representation and warranty shall not apply to any statements or omissions made in
reliance upon and in conformity with information furnished in writing to the Company by or
on behalf of the Underwriter or any Selling Stockholder expressly for use therein;
(c) For the purposes of this Agreement, the “Applicable Time” is 9:45p.m. (New York
time) on the date of this Agreement. The Pricing Prospectus, as of the Applicable Time, did
not include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; and each Issuer Free Writing Prospectus listed on
Schedule 3(a) hereto does not conflict with the information contained in the Registration
Statement, the Pricing Prospectus or the Prospectus and each such Issuer Free Writing
Prospectus, as supplemented by and taken together with the Pricing Prospectus as of the
Applicable Time and the information included on Schedule 3(b) hereto, did not include any
untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made,
not misleading; provided, however, that this representation and warranty
shall not apply to statements or omissions made in the Pricing Prospectus or an Issuer Free
Writing Prospectus in reliance upon and in conformity with information furnished in writing
to the Company by or on behalf of the Underwriter or any Selling Stockholder expressly for
use therein;
2
(d) The documents incorporated by reference in the Pricing Prospectus and the
Prospectus, when they became effective or were filed with the Commission, as the case may
be, conformed in all material respects to the requirements of the Act or the Exchange Act,
as applicable, and the rules and regulations of the Commission thereunder, and none of such
documents contained an untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements therein not
misleading; and any further documents so filed and incorporated by reference in the
Prospectus or any further amendment or supplement thereto, when such documents become
effective or are filed with the Commission, as the case may be, will conform in all material
respects to the requirements of the Act or the Exchange Act, as applicable, and the rules
and regulations of the Commission thereunder and will not contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading; provided, however, that this
representation and warranty shall not apply to any statements or omissions made in reliance
upon and in conformity with information furnished in writing to the Company by or on behalf
of the Underwriter or any Selling Stockholder expressly for use therein; and no such
documents were filed with the Commission since the Commission’s close of business on the
business day immediately prior to the date of this Agreement and prior to the execution of
this Agreement, except as set forth on Schedule 3(c) hereto;
(e) The Registration Statement conforms, and the Prospectus and any further amendments
or supplements to the Registration Statement or the Prospectus will conform, in all material
respects to the requirements of the Act and the rules and regulations of the Commission
thereunder and do not and will not, as of the applicable effective date as to the
Registration Statement and any amendment thereto and as of the applicable filing date as to
the Prospectus and any amendment or supplement thereto, contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading; provided, however, that this
representation and warranty shall not apply to any statements or omissions made in reliance
upon and in conformity with information furnished in writing to the Company by or on behalf
of the Underwriter or any Selling Stockholder expressly for use therein;
(f) Neither the Company nor any subsidiaries has, since the date of the most recent
audited financial statements included or incorporated by reference in the Pricing
Prospectus: (i) incurred any material liability or obligation, direct or contingent, other
than in the ordinary course of business or (ii) entered into any material transaction or
agreement other than in the ordinary course of business, in each case otherwise than as set
forth or contemplated in the Pricing Prospectus; and, since the respective dates as of which
information has been provided in the Registration Statement and the Pricing Prospectus,
there has not been any change in the capital stock or long-term debt of the Company or any
of its “significant subsidiaries” (as such term is defined in Rule 1-02(w) of Regulation S-X
under the Act) (each, a “Significant Subsidiary” and collectively, the
“Significant Subsidiaries”) or any dividend or distribution of any kind declared,
set aside for payment, paid or made by the Company on any class of its capital stock except
as set forth on Schedule 4 hereto (solely with respect to Significant Subsidiaries);
3
(g) The Company and each of its subsidiaries have good and valid title in fee simple
to, or have valid rights to lease or otherwise use, all items of real and personal property
that are material to the respective businesses of the Company and its subsidiaries, in each
case free and clear of all liens, encumbrances, claims and defects and imperfections of
title except those that (A) do not materially interfere with the use made and proposed to be
made of such property by the Company and its subsidiaries, (B) (x) are contemplated by the
Fifth Amended and Restated Credit Agreement dated as of May 9, 2007, as amended through the
date hereof, among the Company, TRW Automotive Intermediate Holdings Corp., TRW Automotive
Inc., certain subsidiaries of the Company, the financial institutions named therein and
JPMorgan Chase Bank as Administrative Agent and Collateral Agent (the “Credit
Agreement”), (y) are contemplated by the receivables arrangements (as such term is used
in the Prospectus) or (z) such as are described in the Pricing Prospectus, or (C) could not
reasonably be expected, individually or in the aggregate, to have a material adverse effect
on the business, financial condition, or results of operations of the Company and its
subsidiaries, taken as a whole (a “Material Adverse Effect”);
(h) The Company and each of its Significant Subsidiaries have been duly organized and
are validly existing and in good standing under the laws of their respective jurisdictions
of organization, are duly qualified to do business and are in good standing in each
jurisdiction in which their respective ownership or lease of property or the conduct of
their respective businesses requires such qualification, and have all corporate power and
authority necessary to own their respective properties and to conduct the businesses in
which they are engaged as described in the Pricing Prospectus, except where the failure to
be so qualified or have such power or authority would not, individually or in the aggregate,
have a Material Adverse Effect;
(i) The Company has an authorized capitalization as set forth in the Pricing Prospectus
and Prospectus and all the issued and outstanding shares of capital stock of the Company
have been duly and validly authorized and issued and are fully paid and non-assessable and
conform to the description of the Stock incorporated by reference in the Pricing Prospectus
and Prospectus; all of the outstanding shares of capital stock of each Significant
Subsidiary of the Company have been duly and validly authorized and issued, are fully paid
and non-assessable and are owned directly or indirectly by the Company, free and clear of
any lien, charge, encumbrance, security interest, restriction upon voting or transfer or any
other claim of any third party, other than those contained in the Credit Agreement;
(j) The Company has the corporate power and authority to execute and deliver this
Agreement and to perform its obligations hereunder; and all corporate action required to be
taken for the due and proper authorization, execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby have been duly and validly taken by the
Company;
(k) This Agreement has been duly authorized, executed and delivered by the Company and
constitutes a valid and legally binding agreement of the Company except as enforceability
may be limited by (A) the effects of bankruptcy, insolvency, fraudulent conveyance,
4
reorganization, moratorium and other similar laws relating to or affecting creditors’
rights generally, (B) general equitable principles (whether considered in a proceeding in
equity or at law) and (C) an implied covenant of good faith and fair dealing;
(l) The Shares have been duly and validly authorized and issued and are fully paid and
non-assessable and conform to the description of the Stock incorporated by reference in the
Prospectus;
(m) The sale of the Shares to be sold by the Selling Stockholders and the compliance by
the Company with all of the provisions of this Agreement and the consummation of the
transactions herein contemplated will not (A) conflict with or result in a breach or
violation of any of the terms or provisions of, or constitute a default under, any
indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
the Company or any of its Significant Subsidiaries is a party or by which the Company or any
of its Significant Subsidiaries is bound or to which any of the property or assets of the
Company or any of its Significant Subsidiaries is subject, except for such conflicts,
breaches, violations, defaults, liens, charges or encumbrances that could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect, (B) result in
any violation of any law or statute or any judgment, order, decree, rule or regulation of
any court or arbitrator or governmental or regulatory authority or body having jurisdiction
over the Company or any of its Significant Subsidiaries or any of their respective
properties or assets, except for such violations that could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect, or (C) result in any
violation of the provisions of the Certificate of Incorporation or By-laws (or similar
organizational documents) of the Company or any of its Significant Subsidiaries; and no
consent, approval, authorization or order of, or filing, qualification or registration with,
any such court or arbitrator or governmental or regulatory authority or body under any such
statute, judgment, order, decree, rule or regulation is required for the sale of the Shares
to be sold by the Selling Stockholders or consummation of the transactions contemplated by
this Agreement, except the registration under the Act and the Exchange Act and such
consents, approvals, authorizations, registrations or qualifications as may be required
under state securities or Blue Sky laws in connection with the purchase and distribution of
the Shares by the Underwriter or to list the Shares on the New York Stock Exchange (the
“Exchange”);
(n) Neither the Company nor any of its Significant Subsidiaries is (A) in violation of
its Certificate of Incorporation or By-laws (or similar organizational documents), (B) in
default in any respect or is alleged by any other party to be in default in any respect, and
no event has occurred which, with notice or lapse of time or both, would constitute such a
default, in the due performance or observance of any term, covenant or condition contained
in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument
to which the Company or any of its Significant Subsidiaries is a party or by which the
Company or any of its Significant Subsidiaries is bound or to which any of the property or
assets of the Company or any of its Significant Subsidiaries is subject or (C) in violation
in any respect of any law or statute or any judgment, order, decree, rule or regulation of
any court or arbitrator or governmental or regulatory authority or body to which it or its
property or assets may be
5
subject, other than, in the case of clauses (B) or (C), such defaults or violations
that could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect;
(o) Other than as set forth in the Pricing Prospectus and Prospectus, there are no
legal or governmental proceedings pending to which the Company or any of its subsidiaries is
a party or of which any property of the Company or any of its subsidiaries is the subject
(A) as to which an adverse determination is reasonably probable and (B) which could
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
and, to the knowledge of the Company, no such proceedings are threatened or contemplated by
governmental authorities or threatened by others;
(p) The Company is not an “investment company”, as such term is defined in the
Investment Company Act of 1940, as amended (the “Investment Company Act”);
(q) (A) (x) At the time of filing the Registration Statement and (y) at the time the
Company or any person acting on its behalf (within the meaning, for this clause only, of
Rule 163(c) under the Act) made any offer relating to the Shares in reliance on the
exemption of Rule 163 under the Act, the Company was a “well-known seasoned issuer” as
defined in Rule 405 under the Act; and (B) at the time of the filing of the Registration
Statement, the Company was not an “ineligible issuer” as defined in Rule 405 under the Act;
(r) Ernst & Young LLP, who has certified certain financial statements of the Company
and its subsidiaries and has audited the Company’s internal control over financial reporting
and management’s assessment thereof, is an independent public accountant as required by the
Act and the rules and regulations of the Commission thereunder;
(s) The Company maintains a system of internal control over financial reporting (as
such term is defined in Rule 13a-15(f) of the Exchange Act) that complies with the
requirements of the Exchange Act and has been designed by the Company’s principal executive
officer and principal financial officer, or under their supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting
principles. The Company’s internal control over financial reporting is effective and the
Company is not aware of any material weaknesses in its internal control over financial
reporting;
(t) Since the date of the latest audited financial statements included or incorporated
by reference in the Pricing Prospectus, there has been no change in the Company’s internal
control over financial reporting that has materially affected, or is reasonably likely to
materially affect, the Company’s internal control over financial reporting;
(u) The Company maintains disclosure controls and procedures (as such term is defined
in Rule 13a-15(e) of the Exchange Act) that comply with the requirements of the Exchange
Act; such disclosure controls and procedures have been designed to ensure that material
information relating to the Company and its subsidiaries is made known to the Company’s
6
principal executive officer and principal financial officer by others within those
entities; and such disclosure controls and procedures are effective;
(v) To the knowledge of the Company, no action has been taken and no statute, rule,
regulation or order has been enacted, adopted or issued by any governmental agency or body
(other than “Blue Sky” laws, regulations or orders) that prevents the sale of the Shares by
the Selling Stockholders in any jurisdiction; no injunction, restraining order or order of
any nature by any Federal or state court of competent jurisdiction has been issued with
respect to the Company that would prevent or suspend the sale by the Selling Stockholders of
the Shares or the use of the Pricing Prospectus and Prospectus in any jurisdiction; no
action, suit or proceeding is pending against or, to the knowledge of the Company,
threatened against or affecting the Company before any court or arbitrator or any
governmental agency, body or official, domestic or foreign, that could reasonably be
expected to restrain, enjoin, interfere with or adversely affect the transactions
contemplated by this Agreement in any material respect;
(w) The Company and each of its subsidiaries possess all licenses, certificates,
permits and other authorizations issued by the appropriate Federal, state, local or foreign
governmental or regulatory authorities or bodies that are necessary for the conduct of their
respective businesses as described in the Pricing Prospectus and Prospectus, except where
the failure to possess the same could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect, and neither the Company nor any of its
subsidiaries has received notification of any revocation or modification of any such
license, certificate, permit or other authorization or has any reason to believe that any
such license, certificate, permit or other authorization will not be renewed in the ordinary
course, except where the failure to possess the same could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect;
(x) The Company and each of its subsidiaries have filed all Federal, state, local and
foreign income and franchise tax returns required to be filed through the date hereof or
have timely filed requests for extensions and such extensions have been granted and have not
expired and have paid all taxes due thereon (or have made adequate provision for such taxes
on their respective balance sheets), except for taxes being contested in good faith for
which adequate reserves have been provided and any such taxes the failure of which to pay or
so file could not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, and no tax deficiency has been determined adversely to the Company
or any of its subsidiaries that, individually or in the aggregate, has had (nor does the
Company or any of its subsidiaries have any knowledge of any tax deficiency that,
individually or in the aggregate, if determined adversely to the Company or any of its
subsidiaries, could reasonably be expected to have) a Material Adverse Effect;
(y) The Company and its subsidiaries have insurance covering their respective
properties, operations, personnel and businesses, which insurance is in amounts and insures
against such losses and risks as is customary for similar businesses or is required by law;
7
(z) No labor dispute with the employees of the Company or any of its subsidiaries
exists or, to the knowledge of the Company, is contemplated or threatened that, individually
or in the aggregate, could reasonably be expected to have a Material Adverse Effect;
(aa) No “prohibited transaction” (as defined in Section 406 of the Employee Retirement
Income Security Act of 1974, as amended, including the regulations and published
interpretations thereunder (“ERISA”), or Section 4975 of the Internal Revenue Code
of 1986, as amended from time to time (the “Code”)) or “accumulated funding
deficiency” (as defined in Section 302 of ERISA) or any of the events set forth in Section
4043(b) of ERISA (other than events with respect to which the 30-day notice requirement
under Section 4043 of ERISA has been waived) has occurred with respect to any employee
benefit plan of the Company or any of its subsidiaries which could reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect; each such employee
benefit plan has been maintained in compliance with its terms and the requirements of
applicable law, including ERISA and the Code, except where any noncompliance, individually
or in the aggregate, could not reasonably be expected to have a Material Adverse Effect; the
Company and its Significant Subsidiaries have not incurred and do not expect to incur
liability under Title IV of ERISA with respect to the termination of, or withdrawal from,
any pension plan which could reasonably be expected, individually or in the aggregate, to
have a Material Adverse Effect;
(bb) Except as described in the Pricing Prospectus and except as could not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse
Effect, (A) neither the Company nor any of its subsidiaries is in violation of any Federal,
state, local or foreign statute, law, rule, regulation, ordinance, code, legally binding
policy or rule of common law or any judicial or legally binding administrative
interpretation thereof, including any judicial or legally binding administrative order,
consent, decree or judgment, relating to pollution or protection of human health, the
environment (including, without limitation, ambient air, surface water, groundwater, land
surface or subsurface strata) or wildlife, including, without limitation, laws and
regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum
products (collectively, “Hazardous Materials”) or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials (collectively, “Environmental Laws”), (B) the Company and its
subsidiaries have all permits, authorizations and approvals required under any applicable
Environmental Laws (except for such permits, authorizations and approvals the failure of
which to possess could not, individually or in the aggregate, reasonably be expected to
result in a Material Adverse Effect) and are each in compliance with their requirements, (C)
there are no pending or, to the knowledge of the Company, threatened administrative,
regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of
noncompliance or violation, investigations or proceedings relating to any Environmental Law
against the Company or any of its subsidiaries and (D) to the knowledge of the Company,
there are no events or circumstances that might reasonably be expected to form the basis of
an order for clean up or remediation, or an action, suit or proceeding by any private party
or governmental body or agency, against or affecting the
8
Company or any of its subsidiaries relating to Hazardous Materials or any Environmental
Laws;
(cc) Except as described in the Pricing Prospectus, there are no outstanding
subscriptions, rights, warrants, calls or options to acquire, or instruments convertible
into or exchangeable for, or agreements or understandings with respect to the sale or
issuance of, any shares of capital stock of or other equity or other ownership interest in
the Company;
(dd) Other than this Agreement, neither the Company nor any of its subsidiaries is a
party to any contract, agreement or understanding with any person that would give rise to a
valid claim against the Company or any of its subsidiaries or the Underwriter for a
brokerage commission, finder’s fee or like payment in connection with the offering and sale
of the Shares;
(ee) No forward-looking statement (within the meaning of Section 27A of the Act and
Section 21E of the Exchange Act) contained in the Registration Statement, the Preliminary
Prospectus or the Prospectus has been made or reaffirmed without a reasonable basis or has
been disclosed other than in good faith;
(ff) Neither the Company nor any of its affiliates has taken or will take, directly or
indirectly, any action designed to, or that could reasonably be expected to, cause or result
in any stabilization or manipulation of the price of the Shares; provided that the
Company may acquire Stock in open market transactions for purposes of matching contributions
under its 401K plan to the extent that all such open market transactions comply with the
provisions of Regulation M, as promulgated by the Commission; and
(gg) The Company and its subsidiaries own or possess adequate rights to use all
patents, patent applications, trademarks, service marks, trade names, trademark
registrations, service xxxx registrations, copyrights, licenses and know-how (including
trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) necessary for the conduct of their respective
businesses, except where the failure to own or possess such rights could not reasonably be
expected to have a Material Adverse Effect; and, to the knowledge of the Company, the
conduct of their respective businesses does not conflict with any such rights of others,
except for any such conflicts as could not reasonably be expected to have a Material Adverse
Effect, and the Company and its subsidiaries have not received any written notice of any
claim of infringement of or conflict with any such rights of others (a) as to which an
adverse determination is probable and (b) which could reasonably be expected to have,
individually, a Material Adverse Effect.
(ii) Each Selling Stockholder, severally and not jointly, represents and warrants to, and
agrees with, the Underwriter that:
(a) This Agreement has been duly authorized (with respect to Selling Stockholders who
are not natural persons), executed and delivered by such Selling Stockholder;
9
(b) Such Selling Stockholder, as of the Time of Delivery (as defined in Section 3(i)),
will be the lawful owner of the number of Shares to be sold by such Selling Stockholder
pursuant to this Agreement and, at the Time of Delivery, will have valid title to such
Shares, free and clear of all liens, encumbrances, claims and defects and imperfections of
title;
(c) Such Selling Stockholder has full legal right, power and authority to enter into
this Agreement and to sell, assign, transfer and deliver the Shares to be sold by such
Selling Stockholder pursuant to this Agreement in the manner provided in this Agreement;
(d) Such Selling Stockholder has not taken nor will take, directly or indirectly, any
action designed to, or that could reasonably be expected to, cause or result in any
stabilization or manipulation of the price of the Shares;
(e) No consent, approval, authorization or order of any court or arbitrator or
governmental or regulatory authority or body under any statute or any judgment, order,
decree, rule or regulation of any court or arbitrator or governmental or regulatory
authority or body is required for the sale of the Shares to be sold by such Selling
Stockholder or the consummation by such Selling Stockholder of the transactions contemplated
by this Agreement, except such as may have been obtained under the Act and such as may be
required under state securities or Blue Sky laws in connection with the purchase and
distribution of the Shares by the Underwriter and such other approvals as have been
obtained;
(f) The sale of the Shares to be sold by such Selling Stockholder and the compliance by
such Selling Stockholder with all of the provisions of this Agreement and the consummation
of the transactions herein contemplated will not (A) conflict with or result in a breach or
violation of any of the terms or provisions of, or constitute a default under, any
indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
such Selling Stockholder is a party or by which the such Selling Stockholder is bound or to
which any of the property or assets of such Selling Stockholder is subject, except for such
conflicts, breaches, violations, defaults, liens, charges or encumbrances that could not,
individually or in the aggregate, reasonably be expected to have a material adverse effect
on the business, financial condition, or results of operations of such Selling Stockholder,
(B) result in any violation of any law or statute or any judgment, order, decree, rule or
regulation of any court or arbitrator or governmental or regulatory authority or body having
jurisdiction over such Selling Stockholder or any of its respective properties or assets,
except for such violations that could not, individually or in the aggregate, reasonably be
expected to have a material adverse effect on the business, financial condition, or results
of operations of such Selling Stockholder, or (C) result in any violation of the provisions
of the Certificate of Incorporation or By-laws (or similar organizational documents) of such
Selling Stockholder if such Selling Stockholder is not a natural person;
(g) Other than this Agreement, such Selling Stockholder is not a party to any contract,
agreement or understanding with any person that would give rise to a valid claim against the
Company or any of its subsidiaries or the Underwriter for a brokerage commission, finder’s
fee or like payment in connection with the offering and sale of the Shares;
10
(h) The Registration Statement did not, as of the date as of which any part of such
Registration Statement relating to the Shares became, or is deemed to have become, effective
under the Act, contain an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not
misleading; provided that the representations or warranties set forth in this Section
1(ii)(h) are limited to statements or omissions made in reliance upon and in conformity with
information furnished in writing to the Company by such Selling Stockholder specifically for
use in connection with the preparation thereof;
(i) The Prospectus will not, as of its date and on the Time of Delivery, contain an
untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading; provided that the representations or warranties set
forth in this Section 1(ii)(i) are limited to statements or omissions made in reliance upon
and in conformity with information furnished in writing to the Company by such Selling
Stockholder specifically for use in connection with the preparation thereof.
(j) The Pricing Prospectus did not, as of the Applicable Time, contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading, except that the price of the Shares and disclosures directly
relating thereto will be included on the cover page of the Prospectus; provided that the
representations or warranties set forth in this Section 1(i)(j) are limited to statements or
omissions made in reliance upon and in conformity with information furnished in writing to
the Company by such Selling Stockholder specifically for use in connection with the
preparation thereof.
2. (i) Subject to the terms and conditions herein set forth, each Selling Stockholder
agrees, severally and not jointly, to sell to the Underwriter, and the Underwriter agrees to
purchase from each Selling Stockholder, at a purchase price per share of $40.45, the number of
Shares (subject to such adjustment as the Underwriter may determine to eliminate fractional shares)
set forth opposite its name in Schedule 1 hereto.
(ii) Upon the authorization by you of the release of the Shares, you propose to offer the
Shares for sale upon the terms and conditions set forth in the Prospectus.
3. (i) Payment of the purchase price for the Shares shall be made to each of the Selling
Stockholders by Federal Funds wire transfer, against delivery of the certificates for the Shares to
the Underwriter through the facilities of The Depository Trust Company (“DTC”) for the
respective accounts of the Underwriter. Such payment and delivery shall be made at 10:00 a.m., New
York City time, on June 4, 2007 (unless another time shall be agreed to by you, the Selling
Stockholders and the Company). The time at which such payment and delivery are to be made is
hereinafter sometimes called “Time of Delivery.” Electronic transfer of the Shares shall be made
to the Underwriter at the Time of Delivery in such names and in such denominations as the
Underwriter shall specify.
11
(ii) The documents to be delivered at the Time of Delivery by or on behalf of the parties
hereto pursuant to Section 7 hereof, including the cross-receipt for the Shares and any additional
documents requested by the Underwriter pursuant to Section 7(m) hereof, will be delivered at the
offices of Cravath, Swaine & Xxxxx LLP, 000 Xxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx, 00000 (the
“Closing Location”), and the Shares will be delivered at the Closing Location, all at the
Time of Delivery. A meeting will be held at the Closing Location at 2:00 p.m., New York City time,
on the New York Business Day next preceding the Time of Delivery at which meeting the final drafts
of the documents to be delivered pursuant to the preceding sentence will be available for review by
the parties hereto. For the purposes of this Agreement, “New York Business Day” shall mean
each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking
institutions in New York City are generally authorized or obligated by law or executive order to
close.
4. (i) The Company agrees with the Underwriter:
(a) To prepare the Prospectus in a form approved by you and to file such Prospectus
pursuant to Rule 424(b) under the Act not later than the Commission’s close of business on
the second business day following the execution and delivery of this Agreement; to make no
further amendment or any supplement to the Registration Statement, the Basic Prospectus or
the Prospectus prior to the last Time of Delivery, to which you reasonably object promptly
after reasonable notice thereof; to advise you, promptly after it receives notice thereof,
of the time when any amendment to the Registration Statement has been filed or becomes
effective or any amendment or supplement to the Prospectus has been filed and to furnish you
with copies thereof; to advise you, promptly after it receives notice thereof, of the
issuance by the Commission of any stop order or of any order preventing or suspending the
use of any Preliminary Prospectus or Prospectus, of the suspension of the qualification of
the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any
proceeding for any such purpose, or of any request by the Commission for the amending or
supplementing of the Registration Statement or Prospectus or for additional information;
and, in the event of the issuance of any stop order or of any order preventing or suspending
the use of any Preliminary Prospectus or Prospectus or suspending any such qualification,
promptly to use its best efforts to obtain the withdrawal of such order;
(b) If required by Rule 430B(h) under the Act, to prepare a form of prospectus in a
form approved by you and to file such form of prospectus pursuant to Rule 424(b) under the
Act not later than may be required by Rule 424(b) under the Act; and to make no further
amendment or supplement to such form of prospectus to which you reasonably object promptly
after reasonable notice thereof;
(c) Promptly from time to time to take such action as you may reasonably request to
qualify the Shares for offering and sale under the securities laws of such United States
jurisdictions as you may request and to comply with such laws so as to permit the
continuance of sales and dealings therein in such jurisdictions for as long as may be
necessary to complete the distribution of the Shares; provided that in connection
therewith the Company shall not be
12
required to qualify as a foreign corporation or to file a general consent to service of
process in any jurisdiction;
(d) Prior to 10:00 a.m., New York City time, on the New York Business Day next
succeeding the date of this Agreement and from time to time, to furnish you with written and
electronic copies of the Prospectus in New York City in such quantities as you may
reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice
referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of
nine months after the time of issue of the Prospectus in connection with the offering or
sale of the Shares and if at such time any event shall have occurred as a result of which
the Prospectus as then amended or supplemented would include an untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made when such Prospectus
(or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is delivered, not
misleading, or, if for any other reason it shall be necessary during such same period to
amend or supplement the Prospectus or to file under the Exchange Act any document
incorporated by reference in the Prospectus in order to comply with the Act or the Exchange
Act, to notify you and upon your request to file such document and to prepare and furnish
without charge to you and to any dealer in securities as many written and electronic copies
as you may from time to time reasonably request of an amended Prospectus or a supplement to
the Prospectus which will correct such statement or omission or effect such compliance; and
in case you are required to deliver a prospectus (or in lieu thereof, the notice referred to
in Rule 173(a) under the Act) in connection with sales of any of the Shares at any time nine
months or more after the time of issue of the Prospectus, at your request and expense, to
prepare and deliver to you as many written and electronic copies as you may reasonably
request of an amended or supplemented Prospectus complying with Section 10(a)(3) of the Act;
(e) During the period beginning from the date hereof and continuing to and including
the date that is 75 days after the date of the Prospectus, not to offer, sell, contract to
sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of,
except as provided hereunder, any securities of the Company that are substantially similar
to the Shares, including but not limited to any options or warrants to purchase shares of
Stock or any securities that are convertible into or exchangeable for, or that represent the
right to receive, Stock or any such substantially similar securities without the prior
written consent of the Underwriter. The foregoing restriction shall not apply to (i) the
issuance by the Company of shares of Stock upon the exercise of an option or warrant or upon
the conversion or exchange of convertible or exchangeable securities in each case
outstanding on the date of the Prospectus, (ii) the issuance of Stock or grant of an option
to purchase Stock under the Company’s stock plans described or incorporated by reference in
the Prospectus, (iii) the issuance of shares of Stock in connection with the acquisition of
another company; provided that the aggregate market value of such securities may not
exceed 5% of the market capitalization of the Company as of the date hereof and the
recipients of such shares of Stock agree to be bound by the restrictions contained in this
paragraph for 75 days after the date of the Prospectus, (iv) the filing of a registration
statement in respect of the Stock within 75 days
13
from the date of the Prospectus; provided that the Company obtains your prior
written consent (other than a registration statement on Form S-8 with respect to the
Company’s 401K plan or stock incentive plan), (v) subject to Section 4(ii)(a), transactions
by any person other than the Company relating to shares of Stock or other securities
acquired in open market transactions after the completion of the
offering, (vi) transfers of shares of Stock or any security convertible, exchangeable for or exercisable into Stock as a
bona fide gift or gifts as a result of the operation of law or testate or intestate
succession; provided that the transferee agrees to be bound by the same terms as the
transferor under this Section 4(i)(e) or (vii) transfers to a trust, partnership, limited
liability company or other entity, the beneficial interests of which are held by the
transferor; provided that the transferee agrees to be bound by the same terms as the
transferor under this Section 4(i)(e);
(f) If the Company elects to rely upon Rule 462(b), the Company shall file a Rule
462(b) Registration Statement with the Commission in compliance with Rule 462(b) by 10:00
p.m., Washington, D.C. time, on the date of this Agreement, and the Company shall at the
time of filing either pay or cause the Selling Stockholder to (A) pay to the Commission the
filing fee for the Rule 462(b) Registration Statement or (B) give irrevocable instructions
for such payment of such fee pursuant to Rule 111(b) under the Act; and
(g) Upon request by the Underwriter, to furnish, or cause to be furnished, to the
Underwriter an electronic version of the Company’s name and corporate logo for use on the
website, if any, operated by you for the purpose of facilitating the on-line offering of the
Shares (the “License”); provided, however, that the License shall be
used solely for the purpose described above, is granted without any fee and may not be
assigned or transferred; and provided further that the License shall expire on the
date that is nine months after the date hereof.
(ii) Each Selling Stockholder, severally and not jointly, agrees with the Underwriter that:
(a) During the period beginning from the date hereof and continuing to and including
the date that is 75 days after the date of the Prospectus, such Selling Stockholder will not
offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or
otherwise dispose of, except as provided hereunder, any securities of the Company that are
substantially similar to the Shares, including but not limited to any options or warrants to
purchase shares of Stock or any securities that are convertible into or exchangeable for, or
that represent the right to receive, Stock or any such substantially similar securities
without the prior written consent of the Underwriter. The foregoing restriction shall not
apply to (i) the Shares to be sold by such Selling Stockholder hereunder and the exercise of
employee stock options to obtain the Shares to be sold hereunder, (ii) the filing of a
registration statement in respect of the Stock within 75 days from the date of the
Prospectus; provided that such Selling Stockholder obtains the prior written consent of the
Underwriter, (iii) transactions relating to shares of Stock or other securities acquired in
open market transactions after the completion of the offering, (iv) transfers of shares of
Stock or any security convertible, exchangeable for or exercisable into
14
Stock as a bona fide gift or gifts as a result of the operation of law or testate or
intestate succession; provided that the transferee agrees to be bound by the same terms as
the transferor under this Section 4(ii)(a); or (v) transfers to a trust, partnership,
limited liability company or other entity, the beneficial interests of which are held by the
transferor; provided that the transferee agrees to be bound by the same terms as the
transferor under this Section 4(ii)(a); and
(b) Without the prior written consent of the Underwriter, such Selling Stockholder has
not made any offer relating to the Shares that would constitute a “free writing prospectus”
(as defined in Rule 405), any portion of which would be required to be filed with the
Commission; any such free writing prospectus the use of which has been consented to by the
Company is listed on Schedule 3 hereto.
5. (i) The Company represents and agrees that, without your prior consent, it has not
made and will not make any offer relating to the Shares that would constitute a “free
writing prospectus” as defined in Rule 405 under the Act; the Underwriter represents and
agrees that, without the prior consent of the Company, it has not made and will not make any
offer relating to the Shares that would constitute a free writing prospectus; any such free
writing prospectus the use of which has been consented to by the Company is listed on
Schedule 3(a) hereto;
(ii) The Company has complied and will comply with the requirements of Rule 433 under
the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the
Commission or retention where required and legending; and
(iii) The Company agrees that if at any time following issuance of an Issuer Free
Writing Prospectus any event occurred or occurs as a result of which such Issuer Free
Writing Prospectus would conflict with the information in the Registration Statement, the
Pricing Prospectus or the Prospectus or would include an untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements therein, in the
light of the circumstances then prevailing, not misleading, the Company will give prompt
notice thereof to the Underwriter and, if requested by the Underwriter, will prepare and
furnish without charge to the Underwriter an Issuer Free Writing Prospectus or other
document which will correct such conflict, statement or omission; provided,
however, that this representation and warranty shall not apply to any statements or
omissions in an Issuer Free Writing Prospectus made in reliance upon and in conformity with
information furnished in writing to the Company by or on behalf of the Underwriter expressly
for use therein.
6. The Company covenants and agrees with the Underwriter that the Company will pay the
following: (i) the fees, disbursements and expenses of the Company’s counsel and accountants in
connection with the registration of the Shares under the Act and all other expenses in connection
with the preparation, printing and filing of the Registration Statement, the Basic Prospectus, any
Preliminary Prospectus, any Issuer Free Writing Prospectus and the Prospectus and amendments and
supplements thereto and the mailing and delivering of copies thereof to the Underwriter and
dealers; (ii) the cost of printing or producing the Blue Sky Memorandum and any other documents
prepared in connection with the offering, purchase, sale and delivery of the Shares under state
securities laws; (iii)
15
all expenses in connection with the qualification of the Shares for offering and sale under
state securities laws as provided in Section 4(i)(c) hereof, including the reasonable fees and
disbursements of counsel for the Underwriter in connection with such qualification and in
connection with the Blue Sky Memorandum; (iv) all fees and expenses in connection with listing the
Shares on the Exchange, if any; (v) the filing fees incident to, and the reasonable fees and
disbursements of counsel for the Underwriter in connection with, securing any required review by
the National Association of Securities Dealers, Inc. of the terms of the sale of the Shares; (vi)
the cost of preparing stock certificates; (vii) the cost and charges of any transfer agent or
registrar; (viii) all other costs and expenses incident to the performance by the Company and the
Selling Stockholders of their respective obligations hereunder which are not otherwise specifically
provided for in this Section. It is understood, however, that, except as provided in this Section,
and Sections 8 and 11 hereof, the Underwriter will pay all of their own costs and expenses,
including the fees of their counsel, transfer taxes on resale of any of the Shares by them, and any
advertising expenses connected with any offers they may make. The provisions of this Section shall
not supersede or otherwise affect any agreement that the Company and the Selling Stockholders may
otherwise have for the allocation of such expenses between themselves.
7. The obligation of the Underwriter hereunder, as to the Shares to be delivered at the Time
of Delivery, shall be subject, in its discretion, to the condition that all representations and
warranties and other statements of the Company and each of the Selling Stockholders herein are, at
and as of the Time of Delivery, true and correct, the condition that the Company and each of the
Selling Stockholders shall have performed all of their respective obligations hereunder theretofore
to be performed, and the following additional conditions:
(a) The Prospectus shall have been filed with the Commission pursuant to Rule 424(b)
under the Act within the applicable time period prescribed for such filing by the rules and
regulations under the Act and in accordance with Section 4(i)(a) hereof; if the Company has
chosen to rely on Rule 462(b), the Rule 462(b) Registration Statement shall have become
effective by 10:00 p.m., Washington, D.C. time, on the date of this Agreement; all material
required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been
filed with the Commission within the applicable time period prescribed for such filings by
Rule 433; no stop order suspending the effectiveness of the Registration Statement or any
part thereof shall have been issued and no proceeding for that purpose shall have been
initiated or threatened by the Commission and no notice of objection of the Commission to
the use of the Registration Statement or any post-effective amendment thereto pursuant to
Rule 401(g)(2) under the Act shall have been received; no stop order suspending or
preventing the use of the Prospectus or any Issuer Free Writing Prospectus shall have been
initiated or threatened by the Commission; and all requests for additional information on
the part of the Commission shall have been complied with to your reasonable satisfaction;
(b) Cravath, Swaine & Xxxxx LLP, counsel for the Underwriter, shall have furnished to
you its written opinion and 10b-5 letter (in the forms attached as Annex A-1 and Annex A-2
hereto), dated the Time of Delivery and such counsel shall have received such papers and
information as they may reasonably request to enable them to pass upon such matters;
16
(c) Xxxxxxx Xxxxxxx & Xxxxxxxx LLP, counsel for the Company, shall have furnished to
the Underwriter its written opinion and negative assurance statement (in the forms attached
as Annex B-1 and Annex B-2 hereto), dated the Time of Delivery, in form and substance
reasonably satisfactory to the Underwriter;
(d) Xxxxx X. Xxxxxxxx, Esq., General Counsel of the Company, shall have furnished to
you his written opinion (in the form attached as Annex C hereto), dated the Time of
Delivery;
(e) Xxxxxxx Xxxxxxx & Xxxxxxxx LLP, counsel for the Selling Stockholders, shall have
furnished to you its written opinion (in the forms attached as Annex B-1 hereto), dated such
Time of Delivery, in form and substance reasonably satisfactory to you;
(f) On the date of the Pricing Prospectus upon execution of this Agreement, at 9:45
p.m., New York City time, on the effective date of any post-effective amendment to the
Registration Statement filed subsequent to the date of this Agreement and also at the Time
of Delivery, Ernst & Young LLP shall have furnished to you a letter or letters, dated the
respective dates of delivery thereof, in form and substance satisfactory to you, to the
effect set forth in Annex D hereto;
(g) Subsequent to the execution and delivery of this Agreement, no event or condition
of a type described in Section 1(i)(f) shall have occurred or shall exist, which event or
condition is not described in the Pricing Prospectus, the effect of which in your judgment
makes it impracticable or inadvisable to proceed with the public offering or the delivery of
the Shares being delivered at the Time of Delivery on the terms and in the manner
contemplated in the Prospectus;
(h) On or after the Applicable Time (i) no downgrading shall have occurred in the
rating accorded the Company’s debt securities by any “nationally recognized statistical
rating organization”, as such term is defined by the Commission for purposes of Rule
436(g)(2) under the Act; and (ii) no such organization shall have publicly announced that it
has under surveillance or review, with possible negative implications, its rating of any of
the Company’s debt securities;
(i) On or after the Applicable Time there shall not have occurred any of the following:
(i) a suspension or material limitation in trading in securities generally on the Exchange;
(ii) a suspension or material limitation in trading in the Company’s securities on the
Exchange; (iii) a general moratorium on commercial banking activities declared by either
Federal or New York State authorities or a material disruption in commercial banking or
securities settlement or clearance services in the United States; (iv) the outbreak or
escalation of hostilities involving the United States or the declaration by the United
States of a national emergency or war; or (v) the occurrence of any other calamity or crisis
or any change in financial, political or economic conditions in the United States or
elsewhere, if the effect of any such event specified in clause (iv) or (v) in the judgment
of the Underwriter is so material and adverse as to make it impracticable or inadvisable to
proceed with the public offering or the delivery of the Shares
17
being delivered at the Time of Delivery on the terms and in the manner contemplated in
the Prospectus;
(j) The Company shall have complied with the provisions of Section 4(i)(d) hereof with
respect to the furnishing of prospectuses on the New York Business Day next succeeding the
date of this Agreement;
(k) The Shares shall have been duly listed on the Exchange;
(l) The Company shall have furnished or caused to be furnished to you at the Time of
Delivery a certificate of the chief financial officer of the Company as to the accuracy of
the representations and warranties of the Company herein at and as of such Time of Delivery,
as to the performance by the Company of all of its obligations hereunder to be performed at
or prior to the Time of Delivery, and the Company shall have furnished or caused to be
furnished certificates of the chief financial officer of the Company as to the matters set
forth in subsections (a) and (g) of this Section and as to such other matters as the
Underwriter may reasonably request; and
(m) Each of the Selling Stockholders shall have furnished or caused to be furnished to
you at the Time of Delivery, a certificate, signed by such Selling Stockholder, as to the
accuracy of the representations and warranties of such Selling Stockholder herein at and as
of such Time of Delivery, as to the performance by such Selling Stockholder of all of its
obligations hereunder to be performed at or prior to such Time of Delivery.
8. Indemnifications:
(a) The Company will indemnify and hold harmless the Underwriter against any losses,
claims, damages or liabilities, joint or several, to which the Underwriter may become
subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities
(or actions in respect thereof) arise out of or are based upon an untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement, the
Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or
any amendment or supplement thereto, any Issuer Free Writing Prospectus or any “issuer
information” filed or required to be filed pursuant to Rule 433(d) under the Act, or arise
out of or are based upon the omission or alleged omission to state therein a material fact
or necessary to make the statements therein not misleading, and will reimburse the
Underwriter for any legal or other expenses reasonably incurred by the Underwriter in
connection with investigating or defending any such action or claim as such expenses are
incurred; provided, however, that the Company shall not be liable in any
such case to the extent that any such loss, claim, damage or liability arises out of or is
based upon an untrue statement or alleged untrue statement or omission or alleged omission
made in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the
Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer
Free Writing Prospectus, in reliance upon and in conformity with written information
furnished to the Company by or behalf of the Underwriter or any Selling Stockholder
expressly for use therein.
18
(b) Each Selling Stockholder, severally and not jointly, agrees to indemnify and hold
harmless the Company and the Underwriter to the same extent as the foregoing indemnity from
the Company to the Underwriter, but only with reference to written information furnished to
the Company by or on behalf of such Selling Stockholder specifically for inclusion in the
documents referred to in the foregoing indemnity; provided, however, that
the Selling Stockholders will not be liable in any such case to the extent that any such
loss, claim, damage or liability arises out of or is based upon an untrue statement or
alleged untrue statement or omission or alleged omission from any of the documents referred
to in the foregoing indemnity in reliance upon and in conformity with written information
furnished to the Company by the Underwriter specifically for use therein.
(c) The Underwriter will indemnify and hold harmless the Company and each Selling
Stockholder against any losses, claims, damages or liabilities to which the Company or such
Selling Stockholder may become subject, under the Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or are based
upon an untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing
Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free
Writing Prospectus, or arise out of or are based upon the omission or alleged omission to
state therein a material fact therein or necessary to make the statements therein not
misleading, in each case to the extent, but only to the extent, that such untrue statement
or alleged untrue statement or omission or alleged omission was made in the Registration
Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the
Prospectus or any such amendment or supplement thereto, or any Issuer Free Writing
Prospectus, in reliance upon and in conformity with written information furnished to the
Company by or on behalf of the Underwriter expressly for use therein; and will reimburse the
Company and each Selling Stockholder for any legal or other expenses reasonably incurred by
the Company or such Selling Stockholder in connection with investigating or defending any
such action or claim as such expenses are incurred.
(d) Promptly after receipt by an indemnified party under subsection (a), (b) or (c)
above of notice of the commencement of any action, such indemnified party shall, if a claim
in respect thereof is to be made against the indemnifying party under such subsection,
notify the indemnifying party in writing of the commencement thereof; provided that,
the omission so to notify the indemnifying party shall not relieve it from any liability
which it may have to any indemnified party under subsection (a), (b) or (c) above except to
the extent that it has been materially prejudiced (through the forfeiture of substantive
rights or defenses) by such failure; and provided further that the omission so to
notify the indemnifying party shall not relieve it from any liability which it may have to
any indemnified party otherwise than under such subsection. In case any such action shall
be brought against any indemnified party and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate therein and,
to the extent that it shall wish, jointly with any other indemnifying party similarly
notified, to assume the defense thereof, with counsel reasonably satisfactory to such
indemnified party (which counsel may at the option of the indemnifying
19
party be counsel to the indemnifying party unless (1) the indemnified party has
reasonably concluded (based upon advice of counsel to the indemnified party) that there may
be legal defenses available to it or other indemnified parties that are different from or in
addition to those available to the indemnifying party or (2) a conflict or potential
conflict exists (based upon advice of counsel to the indemnified party) between the
indemnified party and the indemnifying party), and, after notice from the indemnifying party
to such indemnified party of its election so to assume the defense thereof, the indemnifying
party shall not be liable to such indemnified party under such subsection for any legal
expenses of other counsel or any other expenses, in each case subsequently incurred by such
indemnified party, in connection with the defense thereof other than reasonable costs of
investigation. If the indemnifying party does not assume the defense of such action, it is
understood that the indemnifying party shall not, in connection with any one such action or
separate but substantially similar or related actions in the same jurisdiction arising out
of the same general allegations or circumstances, be liable for the fees and expenses of
more than one separate firm of attorneys (in addition to one separate firm of local
attorneys in each such jurisdiction when reasonably necessary but not to include two firms
in the same jurisdiction) at any time for all such indemnified parties. The indemnifying
party shall not be liable for any settlement of an action or claim for monetary damages
effected without its consent, which consent shall not be unreasonably withheld, but if
settled with such consent or if there is a final judgment for the plaintiff, the
indemnifying party shall indemnify each indemnified party from and against any loss or
liability by reason of such settlement or judgment. No indemnifying party shall, without the
written consent of the indemnified party, effect the settlement or compromise of, or consent
to the entry of any judgment with respect to, any pending or threatened action or claim in
respect of which indemnification or contribution may be sought hereunder (whether or not the
indemnified party is an actual or potential party to such action or claim) unless such
settlement, compromise or judgment (i) includes an unconditional release of the indemnified
party from all liability arising out of such action or claim and (ii) does not include a
statement as to, or an admission of, fault, culpability or a failure to act, by or on behalf
of any indemnified party.
(e) If the indemnification provided for in this Section 8 is unavailable to or
insufficient to hold harmless an indemnified party under subsection (a), (b) or (c) above in
respect of any losses, claims, damages or liabilities (or actions in respect thereof)
referred to therein, then each indemnifying party shall contribute to the amount paid or
payable by such indemnified party as a result of such losses, claims, damages or liabilities
(or actions in respect thereof) in such proportion as is appropriate to reflect the relative
benefits received by the Company, by the Underwriter and by the Selling Stockholders from
the offering of the Shares. If, however, the allocation provided by the immediately
preceding sentence is not permitted by applicable law or if the indemnified party failed to
give the notice required under subsection (d) above, then each indemnifying party shall
contribute to such amount paid or payable by such indemnified party in such proportion as is
appropriate to reflect not only such relative benefits but also the relative fault of the
Company, of the Underwriter and of the Selling Stockholders in connection with the
statements or omissions which resulted in such losses, claims, damages or liabilities (or
actions in respect thereof), as well as any other relevant equitable considerations. The
relative benefits received by the Company and/or by the Selling Stockholders on the one hand
20
and the Underwriter on the other shall be deemed to be in the same proportion as the
total net proceeds from the offering (before deducting expenses) received by the Selling
Stockholders bear to the total underwriting discounts and commissions received by the
Underwriter. The relative fault shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company, the
Underwriter or the Selling Stockholders and the parties’ relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission. The
Company, the Underwriter and the Selling Stockholders agree that it would not be just and
equitable if contribution pursuant to this subsection (e) were determined by pro rata
allocation or by any other method of allocation which does not take account of the equitable
considerations referred to above in this subsection (e). The amount paid or payable by an
indemnified party as a result of the losses, claims, damages or liabilities (or actions in
respect thereof) referred to above in this subsection (e) shall be deemed to include any
legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this
subsection (e), the Underwriter shall not be required to contribute any amount in excess of
the amount by which the total price at which the Shares underwritten by it and distributed
to the public were offered to the public exceeds the amount of any damages which the
Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any
person who was not guilty of such fraudulent misrepresentation.
(f) The obligations of the Company under this Section 8 shall be in addition to any
liability which the Company may otherwise have and shall extend, upon the same terms and
conditions, to each person, if any, who controls the Underwriter within the meaning of the
Act; and the obligations of the Underwriter under this Section 8 shall be in addition to any
liability which the Underwriter may otherwise have and shall extend, upon the same terms and
conditions, to each officer and director of the Company and to each person, if any, who
controls the Company within the meaning of the Act. The obligations of each Selling
Stockholder under this Section 8 shall be in addition to any liability which such Selling
Stockholder may otherwise have.
(g) The liability of each Selling Stockholder under (i) such Selling Stockholder’s
representations and warranties contained in Section 1 and (ii) under this Section 8, in each
case shall be limited to an amount equal to the net proceeds received by such Selling
Stockholder from the Shares sold by the Selling Stockholder to the Underwriter. The Company
and each such Selling Stockholder may agree, as between themselves and without limiting the
rights of the Underwriter under this Agreement, as to the respective amounts of such
liability for which they each shall be responsible. The Underwriter acknowledges and agrees
that the statements relating to each Selling Stockholder under the caption “Selling
Stockholders” in the Prospectus constitute the only information furnished in writing by or
on behalf of such Selling Stockholder expressly for use in the Registration Statement, any
Preliminary Prospectus, the Prospectus or any Selling Stockholder Free Writing Prospectus or
any amendments or supplements thereto.
21
9. Default:
(a) If you shall default in your obligation to purchase the Shares which you have
agreed to purchase hereunder at a Time of Delivery, you may in your discretion arrange for
another party or other parties reasonably satisfactory to the Company and the Selling
Stockholders to purchase such Shares on the terms contained herein. If within thirty-six
hours after such default you do not arrange for the purchase of such Shares, then the
Company and the Selling Stockholders shall be entitled to a further period of thirty-six
hours within which to procure another party or other parties satisfactory to the Company and
the Selling Stockholders to purchase such Shares on such terms. In the event that, within
the respective prescribed periods, you notify the Company and the Selling Stockholders that
you have so arranged for the purchase of such Shares, or the Company and Selling
Stockholders notify you that they have so arranged for the purchase of such Shares, the
Company shall have the right to postpone a Time of Delivery for a period of not more than
seven days, in order to effect whatever changes may thereby be made necessary in the
Registration Statement or the Prospectus, or in any other documents or arrangements, and the
Company agrees to file promptly any amendments or supplements to the Registration Statement
or the Prospectus which may thereby be made necessary. The term “Underwriter” as used in
this Agreement shall include any person substituted under this Section with like effect as
if such person had originally been a party to this Agreement with respect to such Shares.
10. The respective indemnities, agreements, representations, warranties and other statements
of the Company, the Selling Stockholders and the Underwriter, as set forth in this Agreement or
made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force
and effect, regardless of any investigation (or any statement as to the results thereof) made by or
on behalf of the Underwriter or any controlling person of the Underwriter, the Selling Stockholders
or the Company or any officer or director or controlling person of the Company, and shall survive
delivery of and payment for the Shares.
11. If this Agreement shall be terminated pursuant to Section 9 hereof, neither the Company
nor any Selling Stockholder shall be under any liability to the Underwriter except as provided in
Sections 6 and 8 hereof; but, if for any other reason the Shares are not delivered by or on behalf
of the Selling Stockholders as provided herein, the Company will reimburse or cause the Selling
Stockholders to reimburse the Underwriter for all out-of-pocket expenses, including fees and
disbursements of counsel, reasonably incurred by the Underwriter in making preparations for the
purchase, sale and delivery of the Shares not so delivered, but the Company and the Selling
Stockholders shall then be under no further liability to the Underwriter in respect of the Shares
not so delivered except as provided in Sections 6 and 8 hereof.
12. All statements, requests, notices and agreements hereunder shall be in writing, and if to
the Underwriter shall be delivered or sent by mail, telex or facsimile transmission to Banc of
America Securities LLC, 0 Xxxx 00xx Xxxxxx, Xxx Xxxx, Xxx Xxxx 000000, Attention: ELM Legal (Fax:
000-000-0000); provided, however, that any notice to the Underwriter pursuant to
Section 8(d) hereof shall be delivered or sent by mail, telex or facsimile transmission at its
address set forth in its Underwriter’s
22
Questionnaire or telex constituting such Questionnaire, which address will be supplied to the
Company by the Underwriter upon request. Any such statements, requests, notices or agreements
shall take effect upon receipt thereof.
13. This Agreement shall be binding upon, and inure solely to the benefit of, the Underwriter,
the Selling Stockholders, the Company and, to the extent provided in Sections 8 and 10 hereof, the
officers and directors of the Company and each person who controls the Company or the Underwriter,
and their respective heirs, executors, administrators, successors and assigns, and no other person
shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the
Shares from the Underwriter shall be deemed a successor or assign by reason merely of such
purchase.
14. Time shall be of the essence of this Agreement. As used herein, the term “business day”
shall mean any day when the Commission’s office in Washington, D.C. is open for business.
15. The Company and the Selling Stockholders acknowledge and agree that (i) the purchase and
sale of the Shares pursuant to this Agreement is an arm’s-length commercial transaction between the
Company and the Selling Stockholders, on the one hand, and the Underwriter, on the other, (ii) in
connection therewith and with the process leading to such transaction the Underwriter is acting
solely as a principal and not the agent or fiduciary of the Company or the Selling Stockholders,
(iii) the Underwriter has not assumed an advisory or fiduciary responsibility in favor of the
Company or the Selling Stockholders with respect to the offering contemplated hereby or the process
leading thereto (irrespective of whether the Underwriter has advised or is currently advising the
Company or any Selling Stockholder on other matters) or any other obligation to the Company or the
Selling Stockholders except the obligations expressly set forth in this Agreement and (iv) the
Company and the Selling Stockholders have consulted their own legal and financial advisors to the
extent it or they deemed appropriate. The Company and the Selling Stockholders agree that they
will not claim that the Underwriter, or any of them, has rendered advisory services of any nature
or respect, or owes a fiduciary or similar duty to them, in connection with such transaction or the
process leading thereto.
16. The Company and the Selling Stockholders acknowledge that the Underwriter’s research
analysts and research departments are required to be independent from their respective investment
banking divisions and are subject to certain regulations and internal policies, and that the
Underwriter’s research analysts may hold views and make statements or investment recommendations
and/or publish research reports with respect to the Company and/or the offering that differ from
the views of their respective investment banking divisions. The Company and the Selling
Stockholders hereby waive and release, to the fullest extent permitted by law, any claims that they
may have against the Underwriter with respect to any conflict of interest that may arise from the
fact that the views expressed by their respective independent research analysts and research
departments may be different from or inconsistent with the views or advice communicated to the
Company or the Selling Stockholders by the Underwriter’s investment banking divisions. The Company
and the Selling Stockholders acknowledge that the Underwriter is a full service securities firm and
as such from time to time, subject to applicable securities laws, may effect transactions for its
own account or the account
23
of its customers and hold long or short positions in debt or equity securities of the
companies that may be the subject of the transactions contemplated by this Agreement.
17. This Agreement supersedes all prior agreements and understandings (whether written or
oral) between the Company, the Selling Stockholders and the Underwriter, or any of them, with
respect to the subject matter hereof.
18. This Agreement shall be governed by and construed in accordance with the laws of the State
of New York.
19. The Company, each Selling Stockholder and the Underwriter hereby irrevocably waive, to the
fullest extent permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
20. This Agreement may be executed by any one or more of the parties hereto in any number of
counterparts, each of which shall be deemed to be an original, but all such respective counterparts
shall together constitute one and the same instrument.
21. Notwithstanding anything herein to the contrary, the Company and the Selling Stockholders
are authorized, subject to applicable law, to disclose any and all aspects of this potential
transaction that are necessary to support any U.S. Federal income tax benefits expected to be
claimed with respect to such transaction, and all materials of any kind (including tax opinions and
other tax analyses) provided to the Company or the Selling Stockholders relating to that treatment
and structure, without the Underwriter imposing any limitation of any kind. However, any
information relating to the tax treatment and tax structure shall remain confidential (and the
foregoing sentence shall not apply) to the extent necessary to enable any person to comply with
securities laws. For this purpose, “tax structure” is limited to any facts that may be relevant to
that treatment.
If the foregoing is in accordance with your understanding, please sign and return to us four
counterparts hereof, and upon the acceptance hereof by you, this letter and such acceptance hereof
shall constitute a binding agreement between the Underwriter, the Selling Stockholders and the
Company.
24
EXHIBIT 1.1
EXECUTION COPY
Very truly yours, TRW Automotive Holdings Corp. |
||||
By: | /s/ Xxxxxx X. Xxxxxx | |||
Name: | Xxxxxx X. Xxxxxx | |||
Title: | Executive Vice President | |||
and Chief Financial Officer |
Automotive Investors L.L.C. |
||||
By: | /s/ Xxxxxx X. Xxxxxxxx | |||
Name: | Xxxxxx X. Xxxxxxxx | |||
Title: | Manager |
Xxxxxx X. Xxxxxx |
||||
By: | /s/ Xxxxxx X. Xxxxxx | |||
Xxxxxx X. Xxxxxx | ||||
Xxxxx X. Xxxxxxxx |
||||
By: | /s/ Xxxxx X. Xxxxxxxx | |||
Xxxxx X. Xxxxxxxx | ||||
Xxxxx X. Lake |
||||
By: | /s/ Xxxxxx X. Xxxxxx | |||
Xxxxxx X. Xxxxxx by Power of Attorney for | ||||
Xxxxx X. Lake |
Xxxxxx Xxxx |
||||
By: | /s/ Xxxxxx X. Xxxxxx | |||
Xxxxxx X. Xxxxxx by Power of Attorney for | ||||
Xxxxxx Xxxx |
Xxxx X. Plant |
||||
By: | /s/ Xxxxxx X. Xxxxxx | |||
Xxxxxx X. Xxxxxx by Power of Attorney for | ||||
Xxxx X. Plant |
Accepted as of the date hereof:
Banc of America Securities LLC |
||||
By: | /s/ Xxxxxx X. Xxxxxxxx | |||
Name: | Xxxxxx X. Xxxxxxxx | |||
Title: | Managing Director, Equity Capital Markets |
SCHEDULE 1
Total Number of | ||||
Shares | ||||
Underwriter | to be Purchased | |||
Banc of America Securities LLC |
11,000,000 |
SCHEDULE 2
Selling Stockholder | Number of Shares | |||
The Blackstone Group L.P. |
10,000,000 | |||
Xxxx X. Plant |
510,000 | |||
Xxxxxx Xxxx |
200,000 | |||
Xxxxx X. Lake |
80,000 | |||
Xxxxxx X. Xxxxxx |
130,000 | |||
Xxxxx X. Xxxxxxxx |
80,000 |
SCHEDULE 3
1.
|
(a) | Issuer Free Writing Prospectuses: Company Overview, dated May 2007. | ||
2.
|
(b) | Pricing Information: | ||
Number of Shares: 11,000,000 | ||||
Price per Share: $40.45 |
SCHEDULE 4
Significant Subsidiaries
1. | TRW Automotive Holdings Corp. | |
2. | TRW Automotive Ltda. | |
3. | TRW Automotive U.S. LLC | |
4. | TRW Automotive Inc. | |
5. | TRW Automotive Receivables LLC | |
6. | TRW Automotive Intermediate Holdings Corp. | |
7. | TRW Intellectual Property Corp. | |
8. | TRW Limited | |
9. | Xxxxxx-Xxxxx Company | |
10. | Xxxxx Industries Limited | |
11. | LucasVarity | |
12. | LucasVarity Automotive Holding Company | |
13. | Stylealpha Limited | |
14. | Automotive Holdings (UK) Limited | |
15. | Automotive Holdings (France) S.A.S. | |
16. | Xxxxx Investment Finance Limited | |
17. | TRW Airbag Systems GmbH | |
18. | TRW Deutschland Holding GmbH | |
19. | Xxxxx Varity s.r.o. | |
20. | TRW Polska Sp.z o.o. |
ANNEX A-1
[Letterhead of Cravath, Swaine & Xxxxx LLP]
ANNEX A-2
[Letterhead of Cravath, Swaine & Xxxxx LLP]
ANNEX B-1
[Letterhead of Xxxxxxx Xxxxxxx & Xxxxxxxx LLP]
ANNEX B-2
[Letterhead of Xxxxxxx Xxxxxxx & Xxxxxxxx LLP]
ANNEX D
[Letterhead of E&Y]